NEW YORK – BC Platforms said Wednesday that it has closed a $15 million Series C financing round and entered into a strategic partnership with healthcare analytics powerhouse IQvia. Durham, North Carolina-based IQvia led the investment round, with participation from Debiopharm Innovation Fund and Finnish investment firm Tesi.
In their partnership, BC Platforms and IQvia will develop "data-driven technologies" to integrate genomic and clinical data to support biomedical research, the companies said.
More immediately, BC Platforms, of Zurich, Switzerland, will lend its technology to IQvia's E360 Genomics, an integrated genomic-clinical build of the established E360 data-mining platform. This, the companies said, will support a federated genomic analytics network designed to safeguard patient privacy.
"Together with IQVIA's deep healthcare expertise in managing and curating real-world data, we believe that we can accelerate precision medicine initiatives for patient benefits. This funding and commercial collaboration will help accelerate our growth in serving healthcare and life science customers as well as connecting data partners in a global, interoperable federated network," BC Platforms CEO Tero Silvola said in a statement.
"Drawing insights from integrated clinical-genomics data is a growing need of our life science and healthcare customers," added Rob Kotchie, president of real-world solutions at IQVIA. Kotchie noted that combining BC Platforms' automated workflow technologies with IQVIAs real-world technologies platform will "enable customers to conduct novel research and discover new insights to advance healthcare"